Skip to content
Screener

Septerna, Inc. SEPN Cash & Equivalents

Cash & Equivalents at other companies

Amgen logo
AmgenAMGN
$574M+5.9%
Tectonic Therapeutics logo
Tectonic TherapeuticsTECX
$236.89M-22.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$63.61M+15.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$68.65M-19.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$451.8M+323%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.78B+240%
Enterprise value$1.73B+383%
P/S24.7×-696×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Septerna, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216759
Line itemMarch 31, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$71,605$120,722
Marketable securities275,796270,367
Accounts receivable10,84210,356
Prepaid expenses and other current assets9,8159,519
Total current assets368,058410,964
Marketable securities, non-current174,691157,569

Item 1. Condensed Financial Statements.

FAQ

What is Septerna, Inc.'s cash & equivalents?
Septerna, Inc. (SEPN) reported cash & equivalents of $71.61M in Q1 2026.
How has Septerna, Inc.'s cash & equivalents changed year-over-year?
Septerna, Inc.'s cash & equivalents decreased by 65.9% year-over-year, from $210.05M to $71.61M.
What is the long-term trend for Septerna, Inc.'s cash & equivalents?
Over 2 years (2023 to 2025), Septerna, Inc.'s cash & equivalents has grown at a 16.8% compound annual growth rate (CAGR), from $88.48M to $120.72M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Septerna, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude